In Segment C, participants will get ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until disorder progression or maybe the members are not able to tolerate the study drugs. Ubiquitin-linked proteins that regulate the stability of important Tremendous enhancer-mediated https://abbv-744combinationtherap92579.ssnblog.com/31307496/top-brd4-inhibition-by-abbv-744-in-cancer-research-studies-secrets